



PRESS RELEASE

November 25th, 2015

Novacap supports the innovative startup Alganelle specialised in microalgae

Novacap enters into a partnership with the innovative biotechnology startup Alganelle, specialised in the development and production of high added-value molecules, derived from microalgae, which meet the quality and safety requirements of the cosmetic and biomedical industries. This partnership has been sealed through a minority stake taken by Novacap to finance Alganelle's development.

This partnership with a leading biotechnology startup forms part of the open-innovation approach developed by Novacap as part of its growth strategy and will be effective upon completion of the necessary procedures.

"Alganelle has developed specific know-how in using microalgae for the production of biopolymers through the exceptional properties of these organisms and their abilities to synthesize molecules of interest. We are happy to support Alganelle, who will be soon able to rely on Novacap's recognised industrial and commercial expertise in order to accelerate its developments in cosmetics, pharmacy and biomedicine," Pierre Luzeau, President of Novacap, announced.

"For a young biotechnology company at the development stage such as Alganelle, rapid progress towards the pre-industrialisation phase is crucial. To achieve this, the implementation of relevant industrial partnerships that may offer synergies clearly plays a catalytic role. We are delighted to have found in Novacap an organisational structure that is both solid and flexible at the same time, with short decision-making processes and a management team committed to our project," Ghislaine Tissot-Lécuelle, President of Alganelle, declared.

About Alganelle



Founded in 2013 and based in Bourget-Du-Lac (Savoie, France), Alganelle is an innovative biotechnology startup that specialises in the development and production of high added-value molecules from microalgae used as cell factories. These biopolymers will be sold as a raw material to businesses in the biomedical, pharmaceutical and cosmetic fields. Thanks to its technology and unique know-how, Alganelle develops and manufactures raw matter that is of a very high quality, safe and derived from environmentally sustainable processes for its clients. Drawing on its expertise, Alganelle also offers its high-potential and alternative platform based on microalgae, to private or public laboratories. The aim of these feasibility and/or co-development studies is to optimise the quantitative and/or qualitative bioproduction of molecules of interest to their clients. contact@alganelle.com – www.alganelle.com





PRESS RELEASE

November 25th, 2015

About Novacap

Novacap is a global diversified chemicals group that produces and distributes essential chemicals that are used in everyday products and enjoys leading positions in its target growing end-markets of pharmaceutical & healthcare, food & feed, cosmetics & fragrances, home care and environment. The group is an industry leader across a wide range of products including aspirin, paracetamol, other APIs, ketamine, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol and oxygenated solvents, hydrochloric acid and ferric chloride. With an increasing international footprint fueled by organic growth, acquisitions and solid partnerships, the group is experiencing sustainable and profitable growth, demonstrating its entrepreneurial spirit and audacious strategy. Novacap is a supplier to more than 750 customers across more than 80 countries and has made sustainable development a key priority, combining respect for the environment, economic performance and social responsibility. With 14 worldwide facilities, c.1,600 people and a global commercial network, the group is organized into three business divisions: Mineral Specialties, Pharmaceutical & Cosmetics and Performance Chemicals. Novacap is headquartered in Lyon (France). Contact Nathalie Vallier Head of Communications and Investor Relations, nathalie.vallier@novacap.eu - www.novacap.eu

